Free Trial

Olema Pharmaceuticals (OLMA) Competitors

Olema Pharmaceuticals logo
$5.16 +0.15 (+2.99%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$5.17 +0.01 (+0.19%)
As of 05/22/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OLMA vs. CALT, ETNB, OCUL, AMPH, BGM, AUPH, WVE, GYRE, PAHC, and MLYS

Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), Ocular Therapeutix (OCUL), Amphastar Pharmaceuticals (AMPH), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Gyre Therapeutics (GYRE), Phibro Animal Health (PAHC), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry.

Olema Pharmaceuticals vs.

Olema Pharmaceuticals (NASDAQ:OLMA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.

Olema Pharmaceuticals received 12 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 72.22% of users gave Olema Pharmaceuticals an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.

CompanyUnderperformOutperform
Olema PharmaceuticalsOutperform Votes
39
72.22%
Underperform Votes
15
27.78%
Calliditas Therapeutics AB (publ)Outperform Votes
27
55.10%
Underperform Votes
22
44.90%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 19.4% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Olema Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Olema Pharmaceuticals' return on equity of -53.56% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Olema PharmaceuticalsN/A -53.56% -47.86%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

Olema Pharmaceuticals has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Olema Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/A-$96.65M-$2.01-2.57
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62

In the previous week, Olema Pharmaceuticals had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Olema Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Olema Pharmaceuticals' average media sentiment score of 0.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Olema Pharmaceuticals Positive
Calliditas Therapeutics AB (publ) Neutral

Olema Pharmaceuticals presently has a consensus price target of $24.50, indicating a potential upside of 374.81%. Calliditas Therapeutics AB (publ) has a consensus price target of $39.25, indicating a potential downside of 1.88%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Olema Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Olema Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Olema Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OLMA vs. The Competition

MetricOlema PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$353.05M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-2.369.0626.7119.71
Price / SalesN/A251.51386.08120.53
Price / CashN/A65.8538.2534.62
Price / Book1.126.456.774.50
Net Income-$96.65M$143.98M$3.23B$248.22M
7 Day Performance9.55%0.38%0.48%-0.78%
1 Month Performance2.28%2.14%9.10%11.53%
1 Year Performance-40.89%-0.33%18.56%8.99%

Olema Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OLMA
Olema Pharmaceuticals
2.4425 of 5 stars
$5.16
+3.0%
$24.50
+374.8%
-44.0%$353.05MN/A-2.3670
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
$39.25
-1.9%
N/A$1.19B$1.60B-21.62180
ETNB
89bio
2.7231 of 5 stars
$8.11
+5.3%
$27.25
+236.0%
+8.1%$1.18BN/A-2.7940Positive News
OCUL
Ocular Therapeutix
4.2195 of 5 stars
$7.39
+4.7%
$16.25
+119.9%
+20.3%$1.18B$59.65M-5.60230Gap Up
AMPH
Amphastar Pharmaceuticals
4.1677 of 5 stars
$24.34
+1.0%
$32.33
+32.8%
-44.3%$1.15B$730.66M8.111,620
BGM
Qilian International Holding Group
N/A$11.42
+3.5%
N/AN/A$1.11B$25.10M0.00298Positive News
Gap Up
AUPH
Aurinia Pharmaceuticals
2.4142 of 5 stars
$8.12
+1.5%
$11.50
+41.6%
+49.5%$1.11B$235.13M-54.13300
WVE
Wave Life Sciences
4.3742 of 5 stars
$6.60
+0.2%
$21.17
+220.7%
-5.4%$1.02B$108.30M-5.95240Positive News
GYRE
Gyre Therapeutics
0.3745 of 5 stars
$10.83
+13.6%
N/A-17.2%$1.02B$105.76M541.5040News Coverage
PAHC
Phibro Animal Health
3.52 of 5 stars
$24.50
+9.0%
$20.00
-18.4%
+25.0%$992.32M$1.11B51.041,860Positive News
MLYS
Mineralys Therapeutics
2.884 of 5 stars
$15.01
+2.5%
$33.00
+119.9%
+30.4%$973.79MN/A-4.1228Analyst Upgrade
Gap Down

Related Companies and Tools


This page (NASDAQ:OLMA) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners